anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Sarcopenic obesity is a relatively new term. It is a clinical condition characterized by sarcopenia (loss of muscle mass and function) and obesity (increase in fat mass) that mainly affects older adults. As the incidence of sarcopenia and obesity increases worldwide, sarcopenic obesity is becoming a greater problem also in cancer patients. In fact, sarcopenic obesity is associated with poorer treatment outcomes, longer hospital stays, physical disability, and shorter survival in several cancers. Oxidative stress, lipotoxicity, and systemic inflammation, as well as altered expression of skeletal muscle anti-inflammatory myokines in sarcopenic obesity, are also associated with carcinogenesis.
CONCLUSIONS: Reported prevalence of sarcopenic obesity in cancer varies because of heterogeneity in definitions and variability in diagnostic criteria used to estimate the prevalence of sarcopenia and obesity. Therefore, the aim of this review is to describe the definitions, prevalence, and diagnostic criteria as well as the mechanisms that cancer has in common with sarcopenic obesity.
The present application relates to a method of preparing a capsule. "Fecal transplantation" (FMT) refers to the transplantation of functional flora in the feces of healthy people into the gastrointestinal tract of patients to reconstruct new intestinal flora and realize the treatment of intestinal and parenteral diseases. According to clinical findings, some patients can not achieve the due curative effect after taking the codonopsis pilosula, and one of the main reasons of individual difference is that the codonopsis pilosula can not be normally decomposed and converted into active ingredients due to incomplete intestinal flora of the patients, so that the due curative effect of the codonopsis pilosula can not be achieved. According to the application, healthy and high-quality excrement of a fecal bacteria transplant donor is utilized to simulate the enzymolysis of intestinal microorganisms on the codonopsis pilosula saponin in vitro, and the codonopsis pilosula saponin in traditional Chinese medicines such as codonopsis pilosula is degraded and converted into secondary saponin active small molecular substances through proper fermentation conditions, so that the drug effect is exerted. Meanwhile, in the fermentation process, the fructo-oligosaccharide, the codonopsis pilosula polysaccharide and the codonopsis pilosula saponin play a role in improving the intestinal microecology, so that the conversion of the active ingredients of the codonopsis pilosula is facilitated, and a virtuous cycle is formed. The fecal strain fermentation liquor is prepared into fecal strain capsules for clinical fecal strain transplantation treatment.
The patient will be examined by the neurologist at the MS clinic, at the Hadassah University Medical Center. Patients who meet the inclusion criteria will receive an explanation, and will sign informed consent. She will be asked to complete the baseline questionnaires. Than the patient will be assigned to an exercise group. After 12 weeks the patient will be asked to complete post intervention questionnaire. Apart from the weekly lesson, women will be asked to exercise at home for 15 minutes a day. After six months she will be invited again for a neurological examination and filling an additional questionnaire.
Participants will participate in several sessions where they will complete the questionnaires. The questionnaires will be spaced: 0, 1 week, 6 months, 1 year and then at each occupational visit within 5 years.
FIELD: medicinal industry, pharmacy. SUBSTANCE: active component of the preparation is chondroitin sulfates A and C salt. Preparation is prepared by chondroitin sulfate dissolving in distilled water, sterilization, pouring in ampoules and lyophilic drying. Casettes with ampoules were placed in sublimation chamber where chondroitin sulfate solution is frozed to -40-45 C at the rate 10-13 C/h for 5-6 h, kept at this temperature for 5-6 h and subjected for drying by sublimation method by ampoules heating at the rate 5-6 C/h for 13-16 h to 34-36 C and kept at this temperature for 7-10 h. Preparation does not contain preserving agent and retains properties for at least 3 years. EFFECT: improved method of preparing, enhanced quality. 1 tbl
PCT No. PCT/US94/02332 Sec. 371 Date Aug. 23, 1996 Sec. 102(e) Date Aug. 23, 1996 PCT Filed Mar. 4, 1994 PCT Pub. No. WO94/20135 PCT Pub. Date Sep. 15, 1994The anti-viral vaccine of the present invention is produced in transgenic plants and then administered through standard vaccine introduction method or through the consumption of the edible portion of those plants. A DNA sequence encoding for the expression of a surface antigen of a viral pathogen is isolated and ligated to a promoter which can regulate the production of the surface antigen in a transgenic plant. This gene is then transferred to plant cells using a procedure that results in its integration into the plant genome, such as through the use of an Agrobacterium tumefaciens plasmid vector system. Preferably, the foreign gene is expressed in a portion of the plant that is edible by humans or animals. In a preferred procedure, the vaccine is administered through the consumption of the edible plant as food, preferably in the form of a fruit or vegetable juice which can be taken orally.
Objective methods for detecting and diagnosing small cell lung cancer (SCLC) are described herein. In one embodiment, the diagnostic method involves determining the expression level of an SCLC-associated gene that discriminates between SCLC cells and normal cells. In another embodiment, the diagnostic method involves determining the expression level of an SCLC-associated gene that distinguishes two major histological types of lung cancer, non-small cell lung cancer (NSCLC) and SCLC. Finally, the present invention provides methods of screening for therapeutic agents useful in the treatment of small cell lung cancer, methods of treating small cell lung cancer and method for vaccinating a subject against small cell lung cancer. Furthermore, the present invention provides chemotherapy resistant lung cancer- or SCLC-associated genes as diagnostic markers and/or molecular targets for therapeutic agent for these cancers. These genes are up-regulated in chemoresistant lung cancer or SCLC. Accordingly, chemoresistant lung cancer or SCLC can be predicted using expression level of the genes as diagnostic markers. As the result, any adverse effects caused by ineffective chemotherapy can be avoided, and more suitable and effective therapeutic strategy can be selected.
INTRODUCTION: Military experience has demonstrated mortality improvement when advanced resuscitative care (ARC) is provided for trauma patients with severe hemorrhage. The benefits of ARC for trauma in civilian emergency medical services (EMS) systems with short transport intervals are still unknown. We hypothesized that ARC implementation in an urban EMS system would reduce in-hospital mortality.
METHODS: This was a prospective analysis of ARC bundle administration between 2021 and 2023 in an urban EMS system with 70,000 annual responses. The ARC bundle consisted of calcium, tranexamic acid, and packed red blood cells via a rapid infuser. Advanced resuscitative care patients were compared with trauma registry controls from 2016 to 2019. Included were patients with a penetrating injury and systolic blood pressure ≤90 mm Hg. Excluded were isolated head trauma or prehospital cardiac arrest. In-hospital mortality was the primary outcome of interest.
RESULTS: A total of 210 patients (ARC, 61; controls, 149) met the criteria. The median age was 32 years, with no difference in demographics, initial systolic blood pressure or heart rate recorded by EMS, or New Injury Severity Score between groups. At hospital arrival, ARC patients had lower median heart rate and shock index than controls ( p ≤ 0.03). Fewer patients in the ARC group required prehospital advanced airway placement ( p < 0.001). Twenty-four-hour and total in-hospital mortality were lower in the ARC group ( p ≤ 0.04). Multivariable regression revealed an independent reduction in in-hospital mortality with ARC (odds ratio, 0.19; 95% confidence interval, 0.05-0.68; p = 0.01).
CONCLUSION: Early ARC in a fast-paced urban EMS system is achievable and may improve physiologic derangements while decreasing patient mortality. Advanced resuscitative care closer to the point of injury warrants consideration.
LEVEL OF EVIDENCE: Therapeutic/Care Management; Level IV.
NEW MATERIAL:A blood coagulation factor derivative (composed of a polyalkylene glycol having a molecular weight of 200-20,000, containing optionally an alkyl or alkanoyl group as a substituent group and bonded through a coupling agent to the amino acid side chain of a blood coagulation factor). EXAMPLEMonomethyl ether polyethylene glycol-4,6-dichloro-1,3,5-triazine-modified factor IX (PEG5000-IX-4.2mM). USE:Blood coagulation promoting agent. PREPARATION:The objective blood coagulation factor derivative can be prepared by bonding a polyalkylene glycol (e.g. polyethylene glycol) having a molecular weight of 200-20,000 and optionally containing an alkyl group or alkanoyl group as a substituent group through a coupling agent (e.g. cyanuric halide) to the amino acid side-chain of a blood coagulation factor.
OBJECTIVES: This study aimed to determine whether combined of pathogen detection strategies, including specimen acquisition, culture conditions, and molecular diagnostics, can improve treatment outcomes in patients with periprosthetic joint infections (PJI).
METHODS: This retrospective study included suspected PJI cases from three sequential stages at our institution: Stage A (July 2012 to June 2015), Stage B (July 2015 to June 2018), and Stage C (July 2018 to June 2021). Cases were categorized into PJI and aseptic failure (AF) groups based on European Bone and Joint Infection Society (EBJIS) criteria. Utilization of pathogen diagnostic strategies, pathogen detection rates, targeted antibiotic prescription rates, and treatment outcomes were analyzed and compared across the three stages.
RESULTS: A total of 165 PJI cases and 38 AF cases were included in this study. With the progressive implementation of the three optimization approaches across stages A, B and C, pathogen detection rates exhibited a gradual increase (χ2 = 8.282, P=0.016). Similarly, utilization of targeted antibiotic therapy increased stepwise from 57.1% in Stage A, to 82.3% in Stage B, and to 84% in Stage C (χ2 = 9.515, P=0.009). The 2-year infection control rate exceeded 90% in both stages B and C, surpassing stage A (71.4%) (χ2 = 8.317, P=0.011). Combined application of all three optimized protocols yielded the highest sensitivity of 91.21% for pathogen detection, while retaining higher specificity of 92.11%.
CONCLUSION: The utilization of combined pathogen diagnostic strategies in PJI can increase pathogen detection rates, improve targeted antibiotic prescription, reduce the occurrence of antibiotic complications, and achieve better treatment outcomes.
This is a randomised, single blinded, cross-over study comparing the efficacy of metoprolol 100 mg o.d., verapamil 240 mg o.d., diltiazem 360 mg o.d. and carvedilol 25 mg o.d. in reducing ventricular rate in atrial fibrillation. A total of 60 patients will be included, with a minimum of 20 women.Patients will receive each of the drug regimens in a random sequence. Each regimen will be administered for 3 weeks, ensuring that steady-state drug concentration will be attained and to provide an adequate washout of the previous treatment. Following each regimen, exercise ECG and Holter registration will be performed and patients will undergo laboratory evaluation and complete QoL-forms. They will then be started on the next randomly assigned treatment regimen, until the entire sequence of treatment schedules is completed.
OBJECTIVE: To reveal the potential underlying mechanism of the Shenqi Tiaoshen formula (, SQTS) in the treatment of chronic obstructive pulmonary disease (COPD) by utilizing network pharmacology, molecular docking, and experimental verification.
METHODS: Multiple open-source databases and research related to Traditional Chinese Medicine or compounds were employed to screen active ingredients and corresponding potential targets of the SQTS. The protein-protein interaction network screened hub genes, the relevant molecular mechanism and gene regulation were initially identified through the Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) analysis, and molecular docking was used to confirm further the interaction of the main components bound to the core targets. In vivo experiments on the COPD combined Qi-deficiency syndrome rat model were performed to verify the intervention effects and predicted potential molecular mechanisms of the SQTS.
RESULTS: This study selected 156 active compounds and 326 candidate targets for treating COPD. Quercetin, Nobiletin, Kaempferol, Luteolin, Ginsenoside Rh2 and Formononetin were probably the main active compounds of SQTS in COPD treatment as they affected the most COPD-related targets, and interleukin-1 (IL-6), signal transducing activator of transcription 3 (STAT3), matrix metalloproteinase-9 (MMP9), vascular endothelial growth factor A (VEGFA), protein kinase B (AKT1), hypoxia-inducible factor-1α (HIF-1α), and forkhead box O3 (FoxO3) were identified as the hub genes associated with its therapeutic effect. KEGG analysis was mainly enriched in the signaling pathways closely related to inflammation, immunity and oxidative stress, such as HIF-1, tumor necrosis factor (TNF), phosphatidylinositol 3 kinase (PI3K)-AKT, FoxO, apoptosis, IL-17, and toll-like receptor. Molecular docking confirmed that the main active components shared a good affinity with the hub genes. In vivo experiments, the SQTS was found to improve the body weight, exhaustive swimming time, tail-hanging immobility time and struggle times, airway inflammation, lung functions, and inflammatory factors in the rat model of COPD. The up-regulation of p-PI3K, p-AKT, HIF-1α, FoxO3α, toll like receptor 4, VEGFA, Caspase 3, TNF-α, and IL-17 in COPD rats were down-regulated by SQTS, consistent with the network pharmacology results.
CONCLUSIONS: This study provides evidence that the SQTS plays a critical role in anti-inflammation via suppressing immune inflammation and oxidative stress related pathways, indicating that the SQTS is a candidate herbal drug for further investigation in treating COPD.
FIELD: medicine, pharmacology. SUBSTANCE: invention proposes to use maltol obtained in fir wood greens processing. Invention can be used as agent showing bactericidal and fungicide effect in treatment of diseases caused by pathogenic viruses, fungi (yeast) and microorganisms. Invention provides expansion of assortment of preparations of vegetable origin showing bactericidal and fungicide properties. EFFECT: enhanced effectiveness of agent, valuable medicinal properties of agent. 1 tbl
Short arm (20 months): 5 months between every step. Step by step gradual introduction of egg containing food products during 20 months, unless next step can not be taken.
BACKGROUND: Black men and men with end-stage kidney disease have lower rates of treatment and higher mortality for prostate cancer. We studied the interaction of end-stage kidney disease (ESKD) with Black race for treatment rates and mortality for men with prostate cancer.
METHODS AND RESULTS: We included 516 Black and 551 White men with ESKD before prostate cancer 22,299 Black men, and 141,821 White men without ESKD who were 40 years or older from the Surveillance, Epidemiology, and End-Results-Medicare data (2004-2016). All Black men with or without ESKD and White men with ESKD had higher prostate-specific antigen levels at diagnosis than White men without ESKD. Black men with ESKD had the lowest rates for treatment in both local and advanced stages of prostate cancer (age-adjusted risk ratio: 0.76, 95% Confidence Interval (CI): 0.71-0.82 for local stage and age-adjusted risk ratio: 0.82, 95% CI: 0.76-0.9 for advanced stages) compared to White men without ESKD. Compared to White men without ESKD, prostate cancer-specific mortality was higher in White men with ESKD for both local and advanced stages (age-adjusted hazard ratio: 1.8, 95% CI: 1.2-2.8 and HR: 1.6, 95% CI: 1.2-2.2) and it was higher for ESKD Black men only in advanced stage prostate cancer (age-adjusted hazard ratio: 2.4, 95% CI: 1.5-3.6).
CONCLUSION: Our findings suggest that having a comorbidity such as ESKD makes Black men more vulnerable to racial disparities in prostate cancer treatment and mortality.
Reportedly, nausea or vomiting after heavy exercise was associated with post-exercise increased blood calcium (Ca) levels, which was correlated with enhanced bone resorption. We conducted a randomized, double-blind, placebo-controlled trial, enrolling 104 healthy trained male members of the Japan Ground Self-Defense Forces. Risedronate (17.5 mg) or placebo was prescribed 3 and 10 days before heavy exercise lasting approximately 5 h. The primary outcome was the severity of nausea or vomiting assessed by a visual analog scale during or post-exercise. The secondary outcomes included clinical symptoms associated with heat illness, post-exercise serum total Ca (tCa), whole blood ionized Ca (iCa), and serum tartrate-resistant acid phosphatase 5b (TRACP-5b) levels. The mean age was 26 years. The exercise resulted in a 4.5% weight loss. The two groups were comparable in terms of the symptoms, including primary outcome. However, post-exercise tCa and TRACP-5b were significantly lower with risedronate. A similar result was observed for iCa. The post-exercise urinary Ca/Magnesium ratio and the incidence of hypercalcemia (defined as tCa or iCa levels ≥ each median value of all subjects) were significantly lower with risedronate (78.0% vs. 58.5%). A stronger treatment effect of risedronate on blood Ca levels was observed in participants who lost substantial body weight. Post-exercise hypercalcemia is attributed to enhanced bone resorption but not the cause of nausea.
1. Method of production of a combined mumps-measles vaccine which includes infection of primary quail embryo cell culture with mumps and measles viruses, incubation in growth medium containing growth proteins, subsequent rinsing up of the cell culture, incubation and harvesting of virus-containing fluid, characterized in that the mumps and measles viruses are incubated separately in the presence of antibiotic, harvested virus-containing fluid is subjected to clarifying filtration, then stabilizer is added and the fluids are pooled in proportions conforming final vaccination doses: not less than 20,000 TCID50/0.5 ml of mumps component, not less than 1,000 TCID50/0.5 ml of measles component then the preparation is lyophilized. 2. Method according to claim 1, characterized in that mumps virus strain L-3 and measles virus strain L-16 are used as vaccine strains. 3. Method according to claim 2, characterized in that plurality of infection is 0.00001 - 0.001 TCID50 per cell for the mumps virus strain and is 0.001 - 0.01 TCID50 per cell for the measles virus strain. 4. Method according to claim 1, characterized in that incubation is carried out at the temperature from + 34  degree  C to + 36  degree C. 5. Method according to claim 1, characterized in that incubation is carried out in roller plants. 6. Method according to claim 1, characterized in that incubation is carried out in stationary conditions.  7. Method according to claim 1, characterized in that rinsing up of cell culture with supporting medium is carried out not less than 6 times both for mumps and measles components. 8. Method according to claim 1, characterized in that LS-18 with gelatin or sorbitol with gelatose are used as stabilizers. 9. Method according to claim 8, characterized in that polyglucinum or poly-N-vinylpirrolidonum is used as one of stabilizers instead of gelatin or gelatose. 10. Method according to claims 8 or 9, characterized in that poly-N- vinylpirrolidonum with molecular mass not less than 12 kD is used. 11. Method according to claim 1, characterized in that quantity of protein in the combined vaccine does not exceed 8 μg/dose. 12. Method according to claim 1, characterized in that freezing during lyophilization is carried out at the temperature from - 30  degree  C to - 55  degree  C for 3 - 6 hours. 13. Method according to claim 1, characterized in that desiccation during lyophilization is carried out at the temperature from - 17  degree  C to - 28  degree  C for 24 - 60 hours with subsequent heating up to temperature from + 22  degree  C to + 28  degree  C for 8 - 14 hours. 14. Method according to claim 1, characterized in that combined vaccine is prepared with the given concentrations of components determined according to the formula:  Q = T2/T1 * N Where: Q - volume of each starting component, in litres; T1 - starting activity of a component, in TCID50/0.5 ml; T2 - given activity of a component in the combined preparation, in TCID50/0.5 ml; N - given volume of the combined preparation, in litres.
The invention discloses a silver nano hydrogel for regulating flora-activated immune response and a preparation method and application thereof, belonging to the field of biological medicine. The silver nano hydrogel consists of silver nano particles and mucous membrane adhesive gel. The silver nano hydrogel contains inorganic silver nano particles, natural high-molecular polysaccharide, a polyaldehyde-based high-molecular material and a deacetylated high-molecular material. The silver nano hydrogel can adjust the flora abundance of mucous membrane, inhibit the proliferation of other bacteria, and promote the proliferation of immune activation bacteria such as anaerobic digestion streptococcus and the like, thereby enhancing the immune response. Meanwhile, the gel can be adhered to the mucous membrane of the human body, so that the gel can be retained at the affected part for a long time and continuously adjust the symbiotic flora of the human body. The silver nano hydrogel is biodegradable, has excellent biocompatibility, is safe and has no toxic or side effect, and has the advantages of simple preparation, sustainability, high efficiency and the like. The invention has great social and economic significance for the biomedical fields of adjusting symbiotic flora, activating human immunity, assisting in resisting cancer and the like.
After ensuring that the patient\'s characteristics meet the inclusion and exclusion criteria and confirming the patient\'s ability to use the \"voice assistant\", as provided in the research protocol, patients who have completed the briefing will be able to use the voice assistant at home. During the month, robotic remote monitoring of patients using unique algorithms developed for virtual operator speech technology and a BI system will be conducted for five groups of patients (CHF, DM, AH, LPD, and patients who underwent total knee replacement) who have been discharged from the hospital. The system developed allows for quick surveys, collection of data on patient conditions, and convenient transfer of this data to the physician. The physician will receive information on patient status in a graphical form using a traffic light system. In the event of any red flags, the physician will contact the patient for further discussion on treatment strategies. The study will evaluate the efficacy and safety of utilizing the \"voice assistant\" by assessing the achievement of target values for controlled parameters, evaluating patient satisfaction and adherence to treatment, reducing the number of repeat hospitalization, and reducing overall mortality and cardiovascular-related mortality.